Blood test may diagnose lung cancer, company says
WASHINGTON (Reuters) - A blood test that detects nine compounds in blood may offer a safe way to diagnose early cases of lung cancer, Celera Corporation reported on Tuesday.
Such a test would allow quick treatment of lung cancer, which is usually not detected before it has spread, Celera, a newly independent division of Applera Corp. said in a statement.
"This is one of the most promising assays I've seen as a predictor of non-small cell lung cancer," Dr. Harvey Pass of the New York University Langone Medical Center, who helped test the diagnostic, said in a statement.
The researchers tested people who had been diagnosed with stage 1 lung cancer, which can often be cured, and found it detected the cancer with more than 90 percent accuracy.
The test uses a mass spectrometer to detect the nine compounds in the blood. They are also working on a simpler test that looks for six compounds, the researchers told the International Association for the Study of Lung Cancer in San Francisco.
Overall, they tested 103 patients with non-small-cell-lung cancer and smokers without the disease.
Lung cancer is the leading cause of cancer death globally, killing 1.2 million people a year. Most cases are diagnosed after the cancer has spread from the lung, when it cannot be cured.
Maryland-based Celera, founded by gene pioneer Craig Venter as a genetic discovery company, has re-branded itself as a maker of diagnostic tests.
- Mexican train derails, stranding 1,300 migrants headed toward U.S.
- Palestinian death toll rises to 77 as Israel hits Gaza over rocket fire |
- Man charged with murder in Texas shooting deaths of six |
- Wall Street edges lower on Portugal bank worry
- Berlin tells CIA station chief to leave in spy scandal
Robert Blendon of the Harvard School of Public Health says the Affordable Care Act's unpopularity in 12 key states will keep it a central issue in the 2014 elections. Video